Myanmar is one of 22 high tuberculosis (TB) burden countries with a high prevalence of drug-resistant Mycobacterium tuberculosis (MTB) [1] . The Myanmar National Tuberculosis Program uses an algorithm to screen for patients at risk of multidrug-resistant TB (MDR-TB). Patients identified as high risk for MDT-TB are referred to the National Tuberculosis Reference Laboratories, where phenotypic drug susceptibility testing (DST) of the first-line anti-TB drugs isoniazid (INH), rifampicin, ethambutol, and streptomycin is performed for confirmation prior to enrollment in a MDR-TB treatment program [2]. The nationwide drug-resistant TB survey conducted in 2012-2013 identified MDR-TB among 33 (11.2%) of 295 patients in Yangon compared with 35 (4.0%) of 866 outside Yangon. MDR-TB was confirmed among 16 (27.1%) of 58 previously treated patients [3] . Here, we report factors associated with the occurrence of MDR-TB among previously treated TB patients in Yangon. We collected sputum samples with acid-fast bacilli grading 2+ or 3+ from 96 previously treated patients that were referred to the National Tuberculosis Reference Laboratory, Yangon, between October 2012 and August 2013. Isolates were tested for MDR-TB with molecular DST using the Hain GenoType MTBDRplus v1.0 (Hain Lifescience, Nehren, Germany) and phenotypic DST.
fied by logistic regression analysis (Table 1) . Patients in the 19-40 years age group were at greater risk for MDR-TB compared with the 41-60 years age group. Patients living in East and North Districts of Yangon Region were more likely to have MDR-TB than those living in South District. The East and North Districts have large urban populations depending on factory-based employment as well as a large proportion of migrant workers from other states and regions often living in crowded conditions [4] . The most frequently observed resistance mutations were the rpoB S531L (rifampicin) and katG S315T (INH), identified in 67 (84.0%) and 77 (96.0%) of MDR isolates, respectively, and consistent with previous studies [5, 6] . One isolate had INH resistance results discrepant between the MTBDRplus and phenotypic DST result; INH-susceptible by MTBDRplus, but INH-resistance by phenotypic DST. We used whole-genome sequencing (WGS) to resolve this disagreement and detected a rare mutation G299C in katG conferring INH resistance in this isolate [7] highlighting the added value of WGS in the diagnosis of drug-resistant TB. Treatment after failure patients were more likely to have MDR-TB than relapse patients, suggesting that construction of effective regimens is needed to successfully treat drugresistant TB patients. Given that WGS can identify known resistance mutations to most TB drugs, it can be used to guide personalized treatment of drug-resistant TB patients [8, 9] Excluded due to zero frequency CI = confidence interval; OR = odds ratio; Relapse = a patient who was previously declared cured or treatment completed and is diagnosed with bacteriologically-positive TB); TAD = treatment after default (a patient whose treatment was interrupted for 2 consecutive months or more); TAF = treatment after failure (a patient previously treated for TB, who is started on a retreatment regimen after previous treatment has failed). * p < 0.05 was considered statistically significant.
